What We're Reading: Page 319
Industry reads hand-picked by our editors
Oct 27, 2016
Oct 26, 2016
Oct 25, 2016
-
The Irish Times
Pfizer cuts price of Enbrel to match rival ‘biosimilar’ drug
-
Medical Marketing & Media
New science drives biopharma interest in neurological conditions
-
TheStreet
Global Blood, FDA reach agreement on pivotal trial design for sickle cell disease drug
-
Chicago Tribune
Chicago may license pharma reps as part of battle against opioid abuse
Oct 24, 2016
-
The Economist
The trials of Juno
-
Reuters
Sanders urges Californians to approve drug price ballot measure
-
The Wall Street Journal
National Cancer Institute says researchers didn't quickly tell FDA after two deaths in a lymphoma study
Oct 21, 2016
Oct 20, 2016
-
The Wall Street Journal
Tramadol: The opioid crisis for the rest of the world
-
MIT Technology Review
On patrol with America's top bioterror cop
-
Buzzfeed
Second case emerges of someone on daily PrEP getting HIV
-
Bloomberg
Actelion using combination strategy to attack multiple sclerosis
Oct 19, 2016
-
Xconomy
After 'hubris' and its HCV collapse, can Vertex avoid same mistakes?
-
MIT Technology Review
Gene therapy in U.S. is on track for approval as early as next year
-
BloombergGadfly
Biotech shouldn't sweat the election so much
Previous
